MA40535A - Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 - Google Patents

Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90

Info

Publication number
MA40535A
MA40535A MA040535A MA40535A MA40535A MA 40535 A MA40535 A MA 40535A MA 040535 A MA040535 A MA 040535A MA 40535 A MA40535 A MA 40535A MA 40535 A MA40535 A MA 40535A
Authority
MA
Morocco
Prior art keywords
hsp90
therapy
inflammation
infection
infection imaging
Prior art date
Application number
MA040535A
Other languages
English (en)
Inventor
Gabriela Chiosis
Mark Dunphy
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA40535A publication Critical patent/MA40535A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
    • A61B5/02755—Radioactive tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4255—Intestines, colon or appendix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/44—Constructional features of apparatus for radiation diagnosis
    • A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5288—Devices using data or image processing specially adapted for radiation diagnosis involving retrospective matching to a physiological signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/54—Control of apparatus or devices for radiation diagnosis
    • A61B6/541—Control of apparatus or devices for radiation diagnosis involving acquisition triggered by a physiological signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1884—Nanotubes, nanorods or nanowires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)

Abstract

L'invention concerne de nouvelles méthodes d'imagerie d'une inflammation et d'une infection et des applications médicales associées. Dans certains modes de réalisation, l'invention concerne une méthode pour diagnostiquer une inflammation et/ou une infection. Dans certains modes de réalisation, l'invention concerne une méthode pour traiter ou prévenir l'inflammation et/ou l'infection. Dans certains modes de réalisation, la présente invention concerne des méthodes permettant de surveiller l'effet du traitem
MA040535A 2014-09-17 2015-09-17 Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 MA40535A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051590P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
MA40535A true MA40535A (fr) 2016-03-24

Family

ID=55533863

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040535A MA40535A (fr) 2014-09-17 2015-09-17 Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90

Country Status (12)

Country Link
US (3) US10617772B2 (fr)
EP (1) EP3194975A4 (fr)
JP (1) JP6835709B2 (fr)
KR (1) KR20170052687A (fr)
CN (2) CN113521314A (fr)
AU (2) AU2015317632B2 (fr)
BR (1) BR112017005313A2 (fr)
CA (1) CA2961499A1 (fr)
EA (1) EA201790444A1 (fr)
MA (1) MA40535A (fr)
MX (1) MX387627B (fr)
WO (1) WO2016044629A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841069C (fr) 2011-07-08 2021-11-23 Sloan-Kettering Institute For Cancer Research Utilisations d'inhibiteurs de hsp90 marques
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
BR112017005313A2 (pt) * 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
EP3680241A1 (fr) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Compositions de pyrrolopyrrole en tant qu'activateurs de pyruvate kinase (pkr)
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
WO2022162604A1 (fr) 2021-01-28 2022-08-04 (주)아이엠디팜 Cocristal comprenant du camostat et du niclosamide, composition pharmaceutique le comprenant et son procédé de préparation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437145A1 (fr) 2003-01-07 2004-07-14 Schering AG Agents scintigraphiques améliorés pour l'imagerie des infections et inflammations
AU2004235532A1 (en) 2003-05-01 2004-11-11 University Of Liverpool Screening method for identifying Hsp90 modulators
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (fr) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Petites molecules inhibitrices du hsp90
EP1863769A4 (fr) 2005-03-11 2009-03-18 Univ Colorado Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
US20090215742A1 (en) 2005-05-03 2009-08-27 Pfizer, Inc. Amide resorcinol compounds
WO2006123165A2 (fr) 2005-05-19 2006-11-23 Astex Therapeutics Limited Composes pharmaceutiques
WO2006130469A1 (fr) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation de la croissance des neurites au moyen de molecules de petite taille
JP2009533323A (ja) 2006-03-11 2009-09-17 ヴァーナリス アールアンドディー リミテッド Ｈｓｐ９０阻害剤として用いられるピロロピリミジン誘導体
CN101490052B (zh) 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
KR20090104920A (ko) 2007-02-01 2009-10-06 아스트라제네카 아베 Ｈｓｐ90 억제제로서 5,6,7,8-테트라히드로프테리딘 유도체
BRPI0808301B1 (pt) 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
WO2008118391A2 (fr) 2007-03-27 2008-10-02 Synta Pharmaceuticals Corp. Composés qui modulent l'activité hsp90
US8071766B2 (en) 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
MX2011005664A (es) 2008-11-28 2011-06-16 Novartis Ag Inhibidores de hsp90 para tratamiento terapeutico.
WO2010121963A1 (fr) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Dérivés du résorcinol comme inhibiteurs de la hsp90
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011044394A1 (fr) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Dérivés de purine convenant comme inhibiteurs de hsp90
WO2011060253A2 (fr) 2009-11-13 2011-05-19 Myrexis, Inc. Méthodes de traitement de maladies, composés pharmaceutiques, compositions et formes pharmaceutiques
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
US8669248B1 (en) * 2010-09-30 2014-03-11 John Montana Adenine inhibitors of HSP90
EP2694505B1 (fr) * 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Inhibiteurs de la hsp90
EP2694506B1 (fr) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Inhibiteurs de hsp90
WO2012139010A1 (fr) * 2011-04-08 2012-10-11 University Of Kansas Inhibiteurs de grp94
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
CA2841069C (fr) 2011-07-08 2021-11-23 Sloan-Kettering Institute For Cancer Research Utilisations d'inhibiteurs de hsp90 marques
CN102319240A (zh) * 2011-07-19 2012-01-18 厦门大学 去乙酰真菌环氧乙酯作为Hsp90抑制剂的应用
WO2014025395A1 (fr) * 2012-08-06 2014-02-13 Duke University Composés et procédés pour le ciblage de hsp90
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
AU2014386214B2 (en) * 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
EP3131586A4 (fr) * 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques cibles
BR112017005313A2 (pt) * 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90

Also Published As

Publication number Publication date
JP6835709B2 (ja) 2021-02-24
US20210308285A1 (en) 2021-10-07
CN113521314A (zh) 2021-10-22
MX387627B (es) 2025-03-18
JP2017530961A (ja) 2017-10-19
BR112017005313A2 (pt) 2017-12-05
EP3194975A1 (fr) 2017-07-26
CN107110869A (zh) 2017-08-29
EA201790444A1 (ru) 2017-08-31
US20170304470A1 (en) 2017-10-26
US10617772B2 (en) 2020-04-14
AU2022202337A1 (en) 2022-04-28
AU2015317632A1 (en) 2017-04-13
US11065350B2 (en) 2021-07-20
WO2016044629A1 (fr) 2016-03-24
US20200237934A1 (en) 2020-07-30
EP3194975A4 (fr) 2018-05-02
AU2015317632B2 (en) 2022-01-13
MX2017003513A (es) 2017-07-28
KR20170052687A (ko) 2017-05-12
CN107110869B (zh) 2021-08-10
CA2961499A1 (fr) 2016-03-24

Similar Documents

Publication Publication Date Title
MX2024009339A (es) Biomarcadores utiles en el diagnostico de infecciones bacterianas y virales.
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
EP3641644A4 (fr) Système et procédé de diagnostic médical
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
GB2544906B (en) Devices for treating vestibular and other medical impairments.
NZ731467A (en) Anti-tim3 antibodies and methods of use
EP3053619A4 (fr) Seringue médicale, joint utilisé pour une seringue et son procédé de fabrication
EP3258849A4 (fr) Dispositif de filtration d'une pompe médicale, ses procédés de fabrication et d'utilisation
EP3173040A4 (fr) Système de traitement médical ultrasonore, unité de source d'énergie et procédé pour le fonctionnement de l'unité de source d'énergie
GB2541571A (en) Pharmaceutical compositions
EP3253441A4 (fr) Appareil médical comprenant un système implantable et un système externe
EP3263053A4 (fr) Instrument de traitement médical
EP3155971A4 (fr) Dispositif de diagnostic médical, procédé de fonctionnement d'un dispositif de diagnostic médical et programme de fonctionnement d'un dispositif de diagnostic médical
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EP3275393A4 (fr) Dispositif d'observation médicale, dispositif d'observation chirurgicale et système d'observation médicale
EP3520724A4 (fr) Dispositif médical et méthode thérapeutique
MX387627B (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
EP3263152A4 (fr) Dispositif de traitement médical
EP3132420A4 (fr) Appareil d'imagerie médicale et son procédé de fonctionnement
TW201613587A (en) Medical treatments based on anamorelin
PH12017500602A1 (en) Methods for treating ocular conditions
EP2984981A4 (fr) Structure en spirale utilisée pour un endoscope, et endoscope et instrument de traitement comprenant chacun ladite structure en spirale
GB201720419D0 (en) Medical device, wearable device, alert device and methods
EP3145573A4 (fr) Système de traitement médical portable et sa méthode d'utilisation